Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd. C.RVV

Alternate Symbol(s):  RVVTF

Revive has built a robust product pipeline that has a particular focus on infectious diseases and rare disorders and is discovering and developing new therapeutic uses of drugs such as Bucillamine, Psilocybin and Cannabidiol. We are steadily advancing our product development programs that will unlock the potential value of Revive and we are continuing to expand our product pipeline in infectious diseases and rare disorders.


Recent & Breaking News (CSE:RVV)

Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire 12 days ago

Revive Therapeutics To Submit Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire January 12, 2023

Revive Therapeutics (CSE:RVV) closes $4.3M private placement

John Ballem  January 12, 2023

Revive Therapeutics Ltd. Closes $4.3 Million Offering

GlobeNewswire January 12, 2023

Revive Therapeutics Announces Publication Showing Bucillamine's Potential Impact on COVID-19 Omicron Variants

GlobeNewswire January 9, 2023

Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire January 5, 2023

Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire December 22, 2022

Revive Therapeutics Ltd. Expands Life Offering to Quebec

GlobeNewswire December 15, 2022

Revive Therapeutics (CSE:RVV) announces $5M private placement

John Ballem  December 1, 2022

Revive Therapeutics Ltd. Announces Offering of Up to $5 Million

GlobeNewswire November 30, 2022

Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire November 24, 2022

Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

GlobeNewswire November 22, 2022

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

GlobeNewswire October 14, 2022

Revive Therapeutics (CSE:RVV) updates Bucillamine in treating COVID-19

Caroline Egan  October 6, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire October 6, 2022

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

GlobeNewswire September 28, 2022

Revive Therapeutics (CSE:RVV) updates phase I/II clinical study of oral psilocybin

John Ballem  September 16, 2022

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

GlobeNewswire September 16, 2022

CSE Bulletin: INDEX - CSE 25 INDEX QUARTERLY REBALANCING

Newsfile September 15, 2022

Revive Therapeutics (CSE:RVV) submits amended Phase 3 COVID-19 study protocol to FDA

John Ballem  September 14, 2022